Kinfo
Caribou Biosciences, Inc. logo

Caribou Biosciences, Inc.

CRBUNASDAQHealthcare·US · USD
$0.46
-0.02 (-4.37%)
Prices as of October 9, 2026 · market closed

Price

Key statistics

Valuation
Market cap49.32M USD
Enterprise value-19.47M USD
Trailing P/E-0.29
Forward P/E-0.36
PEG ratio0.00
Price / sales4.92
Price / book0.50
Profitability
Gross margin0.00%
Operating margin-1690.39%
Profit margin0.00%
Return on assets-36.85%
Return on equity-78.27%
Income (TTM)
Revenue10.04M USD
Gross profit-73.82M USD
EBITDA-104.61M USD
Net income-103.40M USD
Diluted EPS-$1.08
Rev. growth (YoY)-43.80%
Balance sheet
Total cash112.31M USD
Total debt26.66M USD
Debt / equity27.17
Current ratio6.49
Book value / share$0.93
Cash flow (TTM)
Operating cash flow-95.78M USD
Levered free cash flow-59.61M USD
Shares & price
Shares outstanding106.00M
Float102.91M
Held by institutions44.95%
Beta2.31
50-day MA$1.43
200-day MA$1.72
52-week high$3.54
52-week low$0.44
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-13-0.31-0.24+22.58%2026-07-241.551.68+8.39%2026-06-26-0.120.05+141.67%2026-05-07-0.31-0.26+16.13%2026-03-20-0.18-0.15+16.67%
About Caribou Biosciences, Inc.

Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies using its CRISPR-based chRDNA platform. The company works on off-the-shelf CAR-T and CAR-NK therapies designed to support precise cell engineering for difficult-to-treat diseases. Its current pipeline centers on hematologic malignancies and autoimmune disorders, with programs that include anti-CD19, anti-BCMA, and anti-CD371 cell therapies in clinical development. Caribou Biosciences also applies its gene-editing technology to advance broader research and therapeutic applications in biotechnology. Headquartered in Berkeley, California, the company operates as a single business segment centered on next-generation cell therapy development.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Rachel E. Haurwitz Ph.D.
Employees
97
Headquarters
Berkeley, CA, United States

Frequently asked questions about Caribou Biosciences, Inc.